                         SEQUENCE LISTING

<110>  MEDIMMUNE, LLC
 
<120>  MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE

<130>  AEFC-130-WO-PCT

<150>  US 63/186,445
<151>  2021-05-10

<160>  1     

<170>  PatentIn version 3.5

<210>  1
<211>  208
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  1

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
1               5                   10                  15      


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln 
            20                  25                  30          


Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
        35                  40                  45              


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr 
    50                  55                  60                  


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 
65                  70                  75                  80  


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile 
                85                  90                  95      


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 
            100                 105                 110         


Tyr Thr Phe Pro Pro Glu Gln Glu Glu Met Thr Lys Asn Gln Val Ser 
        115                 120                 125             


Leu Arg Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
    130                 135                 140                 


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Lys Pro 
145                 150                 155                 160 


Val Leu Asp Ser Asp Gly Ser Phe Arg Leu Glu Ser Arg Leu Thr Val 
                165                 170                 175     


Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met 
            180                 185                 190         


His Glu Ala Cys Ser Tyr His Leu Cys Lys Ser Leu Ser Leu Ser Leu 
        195                 200                 205             


